Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Orthop. Aug 18, 2025; 16(8): 107083
Published online Aug 18, 2025. doi: 10.5312/wjo.v16.i8.107083

Table 3 Side effects during and after denosumab therapy, n (%)

Side effects	Frequency
Hypercalcemia	12 (29)
Hypercalcemia + Growth plate ossification	1 (2)
Hypocalcemia + Hypercalcemia	1 (2)
Hypocalcemia + Hypophosphatemia + Hypercalcemia	1 (2)
Hypocalcemia + Hypophosphatemia	1 (2)
Vomiting	1 (2)
Not reported	26 (60)
Total	43

Citation: Machak GN, Bruland ØS, Kovalev AV, Rodionova SS. Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis. World J Orthop 2025; 16(8): 107083
URL: https://www.wjgnet.com/2218-5836/full/v16/i8/107083.htm
DOI: https://dx.doi.org/10.5312/wjo.v16.i8.107083

Machak GN, Bruland ØS, Kovalev AV, Rodionova SS. Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis. World J Orthop 2025; 16(8): 107083 [PMID: 40838228 DOI: 10.5312/wjo.v16.i8.107083]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.